This study aims to determine the effect of online education structured according to Pender's Health Promotion Model on symptom burden, medication adherence, and nutritional behaviour in patients with heart failure. The sample size was calculated using the 'G. Power-3.1.9.2' programme at a 95% confidence level prior to data collection. Accordingly, the minimum sample size required for the independent sample t-test for the study was determined to be 44 (22 for each group) based on an alpha value of 0.05, an effect size of 1.128, and a theoretical power of 95%. Taking data losses into account, a total of 60 patients (30 for each group) were planned to be included in the sample. Data will be collected using the Heart Failure Symptom Status Scale, Medication Adherence and Prescription Printing Scale (İURYÖ-7), Heart Failure Nutrition Behaviour Scale. 1: Prior to providing education to patients, they will be informed about the purpose of the study, the data collection method, and the topics to be covered in the education. Patients who agree to participate in the study will be asked to sign an informed consent form. All patients in the experimental and control groups will be asked to complete the Heart Failure Nutrition Behaviour Scale (HFNBS), Heart Failure Symptom Status Scale (HFSSS), and Medication Adherence and Prescription Writing Scale (MAPWS-79) before receiving education.
2: The contact information of all patients in the experimental group will be collected. Training will be provided online at a time and date convenient for the patients.
3: Patients in the control group will receive a digital training booklet prepared by the researcher at the contact address they provide.
4: Participants will be contacted 2 weeks, 1 month, and 2 months after the initial education session to obtain feedback on post-education dietary behaviours, medication adherence, and symptoms.
5: Four to six weeks after the training is completed, the 'Nutritional Behaviour Scale in Heart Failure,' 'Heart Failure Symptom Status Scale,' and 'Medication Adherence and Prescription Writing Scale (İURYÖ-7)' will be completed online again. The same forms will also be completed online by patients in the control group 4-6 weeks later.

Start Date15 Jul 2025

Sponsor / Collaborator

Canakkale Onsekiz Mart University

NCT07057973

/ RecruitingNot ApplicableIIT

The Effectiveness of Preoperative Iron Therapy in Improving Anemia After Multi-level Lumbar Fusion in the Elderly

Preoperative iron therapy has important value in improving the outcomes after lumbar fusion surgery, but there is significant heterogeneity in both domestic and international studies. International studies provide high-level evidence-based evidence for intravenous iron, but lack spinal surgery-specific data; domestic studies focus on the comparison of iron types and the improvement of clinical practice, but high-quality evidence is still insufficient. At present, there are still few studies on preoperative iron therapy in the field of spinal surgery, especially its specific impact on the prognosis of patients after lumbar fusion surgery is still unclear. Therefore, it is particularly important to study the preoperative iron supplementation regimen for lumbar fusion surgery to improve the efficacy and safety. Through multidisciplinary collaboration and technological innovation, preoperative iron therapy is expected to become an important part of accelerated recovery after lumbar fusion surgery.

Start Date01 Jul 2025

Sponsor / Collaborator

Xuanwu Hospital Capital Medical University

CTRI/2025/06/088448

/ Not yet recruitingNot Applicable

A Double Blind Balanced Randomized Single Dose Two Treatment Parallel Truncated Bioequivalence Study Comparing Ferric Carboxymaltose Injection 50mg Iron per mL 1000mg per 20mL by Jodas Expoim Private Limited Telangana Manufactured For Nova Pharmaceuticals Australasia Pty Ltd With Ferinject Injection Ferric Carboxymaltose 1000mg per 20mL Manufactured by Vifor Pharma Pty Ltd Level 8 80 Dorcas Street Southbank Melbourne Vic 3006 Australia in Adult Patients With Iron Deficiency Anaemia Under Fasting Conditions - NIL

Start Date26 Jun 2025

Sponsor / Collaborator

Nova Pharmaceuticals Australasia Pty Ltd.

100 Clinical Results associated with Ferric Carboxymaltose

100 Translational Medicine associated with Ferric Carboxymaltose

100 Patents (Medical) associated with Ferric Carboxymaltose

862

Literatures (Medical) associated with Ferric Carboxymaltose

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Evaluating the cost-utility of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in Norway

Article

Author: Detlie, T. E. ; Karlsen, L. N. ; Pollock, R. F. ; Nanu, N. ; Jørgensen, E.

AIMS:

Iron deficiency anemia (IDA) is among the most common extraintestinal sequelae of inflammatory bowel disease (IBD). Intravenous iron is often the preferred treatment in patients with active inflammation with or without active bleeding, iron malabsorption, or intolerance to oral iron. The aim of the present study was to evaluate the cost-utility of ferric derisomaltose (FDI) versus ferric carboyxymaltose (FCM) in patients with IBD and IDA in Norway.

MATERIALS AND METHODS:

A published patient-level simulation model was used to evaluate the cost-utility of FDI versus FCM in patients with IBD and IDA from a Norwegian national payer perspective. Iron need was modelled based on bivariate distributions of hemoglobin and bodyweight combined with simplified tables of iron need from the FDI and FCM summaries of product characteristics. Patient characteristics and disease-related quality of life data were obtained from the PHOSPHARE-IBD trial. Cost-utility was evaluated in Norwegian Kroner (NOK) over a five-year time horizon.

RESULTS:

Patients required 1.64 fewer infusions of FDI than FCM over five years (5.62 versus 7.26), corresponding to 0.41 fewer infusions per treatment course. The reduction in the number of infusions resulted in cost savings of NOK 5,236 (NOK 35,830 with FDI versus NOK 41,066 with FCM). The need for phosphate testing in patients treated with FCM resulted in further cost savings with FDI (no costs with FDI versus NOK 4,470 with FCM). Total cost savings with FDI were therefore NOK 9,707. FDI also increased quality-adjusted life expectancy by 0.071 quality-adjusted life years (QALYs) driven by reduced incidence of hypophosphatemia and fewer interactions with the healthcare system.

CONCLUSIONS:

FDI resulted in cost savings and improved quality-adjusted life expectancy versus FCM in patients with IDA and IBD in Norway. FDI therefore represents the economically preferable iron formulation in Norwegian patients with IBD and IDA in whom it is indicated.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

A Swedish cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in the treatment of iron deficiency anemia in patients with inflammatory bowel disease

Article

Author: Manxhuka, Bardh ; Lindgren, Stefan C. ; Strid, Hans ; Nanu, Neesha ; Hjortswang, Henrik ; Pollock, Richard F.

OBJECTIVES:

Iron deficiency anemia (IDA) is a common extraintestinal manifestation of inflammatory bowel disease (IBD), driven by impaired iron absorption, inflammation of intestinal mucosa and blood loss due to intestinal bleeding. Exogenous iron is indicated to correct iron deficiency, with intravenous iron preferred in patients with malabsorption or intolerance of oral iron, active bleeding, systemic inflammation, or a need for rapid iron replenishment. The objective was to assess the cost-utility of two high-dose, rapid-infusion iron formulations-ferric derisomaltose (FDI) and ferric carboxymaltose (FCM)-in the treatment of patients with IBD and IDA in Sweden.

METHODS:

The analysis used a previously-published micro-simulation model. Phosphate monitoring was modeled based on the product labelling, while iron need and disease-related quality of life (QoL) were modeled based on data from the PHOSPHARE-IBD randomized controlled trial. Cost-utility was evaluated from the national healthcare payer perspective over a five-year time horizon. Sensitivity and scenario analyses were performed.

RESULTS:

For each iron treatment course, patients treated with FDI required 0.41 fewer infusions than those treated with FCM. The reduced number of infusions resulted in savings of SEK 9,876 over five years from iron administration costs alone (SEK 44,216 with FCM versus SEK 34,340 with FDI). Phosphate monitoring in patients treated with FCM cost SEK 2,776 over five years versus no monitoring costs with FDI. Total cost savings with FDI were SEK 14,962. FDI also resulted in a 0.076 quality-adjusted life year (QALY) improvement versus FCM driven primarily by the QoL improvements reported in PHOSPHARE-IBD, and FDI was therefore the dominant intervention.

LIMITATIONS:

The analysis did not capture costs or outcomes associated with hypophosphatemic osteomalacia or fractures.

CONCLUSION:

Relative to FCM, fewer infusions of FDI were required, there was no need for phosphate monitoring, and disease-related QoL was improved, while overall costs were reduced.

01 Aug 2025·EJHaem

Cutaneous Reactions to Iron Infusions: A Case Report and Clinical Review

Article

Author: Ravichandran, Sairekha ; Patil, Neil ; Kubal, Timothy ; Kirtane, Kedar ; Phuoc, Vania ; Messina, Jane ; Maharaj, Satish

ABSTRACT:

Anemia is prevalent globally and often treated with intravenous (IV) iron formulations, including iron sucrose, iron dextran, ferric carboxymaltose, ferric derisomaltose, and ferumoxytol. IV iron has a high efficacy and safety profile, quickly improving hemoglobin levels with low rates of adverse events. In this work, we report an uncommon case of a cutaneous hypersensitivity reaction following IV iron. A review of the literature shows that acute and delayed cutaneous reactions are possible but rare and respond well to management. Patients should be educated, and staff should be vigilant as to these cutaneous reactions.Clinical Trial Registration:The authors have confirmed that clinical trial registration is not needed for this submission.

News (Medical) associated with Ferric Carboxymaltose

29 May 2025

·www.sciencedaily.com

Unlocking precise composition analysis of nanomedicines

Current regulations for nanomedicines overlook the effects of the different forms of the same element, such as ions, nanoparticles, and aggregates. In a recent study, researchers developed a new analytical method combining an asymmetric flow field-flow fractionation system and mass spectrometry to separately quantify these forms. This technique allows for better quality control and safety evaluation of metal-based nanomedicines, promoting their development and clinical use, with applications also extending to food, cosmetics, and the environment. Current regulations for nanomedicines overlook the effects of the different forms of the same element, such as ions, nanoparticles, and aggregates. In a recent study, Japanese researchers developed a new analytical method combining an asymmetric flow field-flow fractionation system and mass spectrometry to separately quantify these forms. This technique allows for better quality control and safety evaluation of metal-based nanomedicines, promoting their development and clinical use, with applications also extending to food, cosmetics, and the environment. Nanomedicines, especially those based on nanoparticles, are revolutionizing healthcare in terms of both diagnostics and therapeutics. These particles, often containing metals like iron or gold, can serve as contrast agents in medical imaging, act as nutritional supplements, and even function as carriers for drug delivery. Thanks to their unique properties plus careful engineering, nanomedicines can reach and accumulate in places within the body that conventional medicines cannot, making them promising for cancer detection and treatment. However, the same characteristics that make nanomedicines valuable also present challenges in ensuring their safety and quality. Current pharmaceutical guidelines, including those from the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH), have a significant blind spot: they evaluate only the total amount of elements present in a medication without distinguishing between their different forms, such as ions or differently sized particles. This distinction is crucial because these different forms can have different effects on the body, including varying toxicity pro Against this backdrop, a research team led by Assistant Professor Yu-ki Tanaka from the Graduate School of Pharmaceutical Sciences, Chiba University, Japan, has developed a new analytical method to address the existing regulatory gap. Their study, which was made available online in the journal Talanta on April 8, 2025, introduces a technique to separately quantify ions, nanoparticles, and aggregated particles in nanomedicines. Co-authored by Yasumitsu Ogra and Sana Hasegawa, also from Chiba University, the study showcases how this method can improve quality control for these advanced pharmaceutical products. "By incorporating a novel evaluation method that addresses a previously overlooked issue in current evaluation guidelines, we can ensure the safe use of metal-based nanomedicines such as Resovist® and Ferinject®" explains Dr. Tanaka. The researchers combined two existing technologies -- asymmetric flow field-flow fractionation (AF4) and inductively coupled plasma mass spectrometry (ICP-MS). They used the AF4 method in a novel way, taking advantage of its initial 'focus step.' During this step, particles are held inside the AF4 channel by two opposing flows. Using a special permeable membrane, cross-flows filter out the tiniest dissolved particles (ions), enabling quantification based on the differences in ICP-MS signals between samples with and without ion removal−namely, with and without the focus step. Once the ions are separated, the system then uses AF4's standard separation process to sort the retained nanoparticles by size. Finally, the ICP-MS device attached to the output can determine the approximate number of nanoparticles of each size. This combination enabled the team to distinguish between free metal ions, small hydroxide colloids, and nanoparticles of various sizes, all containing the same metal element. They tested their approach on Resovist®, a nanomedicine used as a contrast agent in liver magnetic resonance imaging scans. The analysis revealed that only 0.022% of the iron in Resovist® was present in ionic form. At approximately 6.3 micrograms per milliliter, this negligible amount falls well below levels of concern. Additionally, the team confirmed that the active nanoparticles were smaller than 30 nanometers in diameter, with some aggregates around 50 nanometers. Importantly, no large aggregates were detected, which could reduce the effectiveness of the contrast agent. These results confirm both the safety and stability of Resovist® as a nanomedicine. The proposed technique is particularly relevant for emerging cancer treatments that use gold nanoparticles as drug delivery systems or metallic particles for photothermal therapy. These advanced treatments rely on the 'enhanced permeability and retention (EPR) effect,' by which nanoparticles leak from blood vessels around tumors and accumulate in cancerous tissue. "Since many novel nanomedicines consist of metal-based nanoparticles as their active ingredients, providing reliable methods for evaluating their safety and quality control will promote their development and clinical use," notes Dr. Tanaka. Additionally, this novel analytical approach extends beyond pharmaceuticals. It can also assess the safety of metal nanoparticles in food additives, cosmetics, and environmental samples -- helping to ensure public health across multiple sectors. The researchers showcased its versatility by successfully analyzing both negatively charged ions (silicon) and positively charged ions (iron), indicating its potential for a wide range of nanomaterials. Overall, by offering a more comprehensive assessment of the composition, quality, and stability of nanoparticles, this research paves the way for safer and more effective nanomedicines and nanoparticle-based technologies.

02 Dec 2024

·www.drugs.com

Guidelines Developed for Treatment of Restless Legs Syndrome

MONDAY, Dec. 2, 2024 -- In a clinical practice guideline issued by the American Academy of Sleep Medicine and published online Sept. 26 in the Journal of Clinical Sleep Medicine , recommendations are presented for the treatment of restless legs syndrome (RLS). John W. Winkelman, M.D., Ph.D., from Massachusetts General Hospital in Boston, and colleagues developed recommendations for treatment of RLS and periodic limb movement disorder in adults and pediatric patients. The researchers developed three good practice statements that were based on expert consensus. They recommend all clinicians should regularly test serum iron studies, including ferritin and transferrin saturation, in all patients with clinically significant RLS, ideally in the morning; analysis of these studies influences the decision to use oral or intravenous (IV) iron treatment. The authors also state that addressing exacerbating factors, including alcohol, caffeine, antihistaminergic, serotonergic, and anti-dopaminergic medications, should be the first step in RLS management. They note RLS is common in pregnancy and the pregnancy-specific safety profile of each treatment should be considered. Recommendations for adults with RLS include use of gabapentin enacarbil over no gabapentin enacarbil; use of gabapentin over no gabapentin; use of pregabalin over no pregabalin; and use of IV ferric carboxymaltose over no IV ferric carboxymaltose for those with appropriate iron status (strong recommendations; moderate certainty of evidence). In addition, there is a strong recommendation against use of cabergoline. "Guided by the best evidence in the scientific literature, we've provided recommendations that will improve the ability of clinicians to provide patient-centered care for people who have RLS," Winkelman said in a statement. One author disclosed ties to the pharmaceutical and medical device industries. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

19 Mar 2024

·www.prnewswire.com

Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure

ST. GALLEN, SWITZERLAND, March 19, 2024 /PRNewswire/ -- CSL Vifor today announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III* 1 to improve exercise capacity.2 Ferinject has now received marketing authorization in 87 countries worldwide. Research shows that rates of iron deficiency are even higher than previously reported in Canada, with the condition particularly prevalent in women of reproductive age3 and children4. "While iron deficiency and associated anemia are some of the most prevalent medical conditions on a global scale, it is easily diagnosed and treatable," said Prof. Dr. Justin Ezekowitz, Director of Cardiovascular Research and Cardiologist at the University of Alberta, Canada. "The news of a new treatment option tested in clinical trials is welcomed, given that oral irons may not be able to adequately deliver the desired outcomes for Canadian patients with heart failure impacted by iron deficiency." Iron deficiency affects one in every two hospitalized patients with heart failure5. Iron deficiency is often accompanied by reduced exercise tolerance and untreated iron deficiency may result in anemia and worsening NYHA class, with reduced quality of life and eventually increased risk of hospitalization 6,7,8 "The approval by Health Canada marks an important step forward for the treatment of iron deficiency anemia as well as iron deficiency in heart failure and supports our promise to patients and public health," said Dr. Vinicius Gomes de Lima, Head of Global Medical Affairs, CSL Vifor. "We are confident that our now approved IV iron therapy can make a meaningful contribution to achieve key therapeutic goals in the treatment of these patients." Marketing authorization in Canada is based on a comprehensive clinical data package and totality of evidence from CSL Vifor's cardiology studies. In Canada, Ferinject® is commercialized through CSL Behring Canada, Inc., with availability expected in the second half of 2024. * The New York Heart Association Functional Classification is used by Healthcare Professionals to classify patients' heart failure based on the severity of their symptoms. Patients who have a slight or marked limitation of their physical activity due to fatigue, palpitation and/or dyspnea are considered to have class II or class III heart failure, respectively.9 About CSL Vifor CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency and nephrology. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care). The parent company, CSL (ASX: CSL; USOTC: CSLLY), headquartered in Melbourne, Australia, employs 32,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor, visit . About Ferinject Ferinject (ferric carboxymaltose) is an IV iron therapy with marketing authorization in 87 countries as of March 2024. Ferinject has historically delivered significant value to patients and healthcare systems which is based on extensive clinical data and more than 25 million patient years of exposure10. In Canada, Ferinject is indicated for the treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and NYHA class II/III to improve exercise capacity. The diagnosis of iron deficiency must be based on laboratory tests.2 Important Information for Canada For more information and a complete risk/benefit profile, please refer to the Product Monograph available here. About iron deficiency and associated anemia Iron plays a vital role in many bodily processes, including the production of red blood cells, effective heart and brain function, and the prevention of infection and illness. Without enough iron, the body is unable to function properly. Common symptoms include fatigue, dizziness, and shortness of breath. Iron deficiency and iron deficiency anemia are estimated to affect one in three people worldwide11, yet despite the serious consequences and high prevalence12, the conditions remain under-recognized. The effects of iron deficiency differ from person to person but can be linked to an overall decline in general health and well-being13. Iron deficiency and iron deficiency anemia can be debilitating, exacerbate an underlying chronic disease and lead to increased morbidity and mortality13. Common symptoms include fatigue 13,14,15 pale skin14, brittle nails14, 16, craving non-food items such as dirt, clay and ice17, and an inability to concentrate13, 18. In children, iron deficiency anemia can significantly impair cognitive and motor development19,20,21. Multiple organizations, including the World Health Organization (WHO), UNICEF and the U.S. Agency for International Development (USAID) have called for a comprehensive anemia monitoring framework. Find more information on the global burden of anemia in the report published in the Lancet in July 2023: . References Fox AC, Gorlin R, Levin RI, New York Heart Association. Criteria Committee. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston, MA: Lippincott Williams and Wilkins; March 1, 1994. Ferinject Product Monograph. CSL Vifor, St. Gallen, Switzerland. Chang V et al. J Nutr 2022 ; 153 : 781–797. doi.org/10.1016/j.tjnut.2022.10.011; Cochrane K et al. J Nutr 2022;152:2238–2244. Tahir E et al. 2020 Can J Public Health 111, 682–693 (2020). doi.org/10.17269/s41997-020-00304-7; Abdullah K et al Canadian Paediatric Surveillance program, 2011 . Del Pinto et al. Eur Heart J Suppl. 2022 Nov; 24(Suppl I): I96–I99). Ebner N, von Haehling S. Iron deficiency in heart failure: a practical guide. Nutrients. 2013;5(9):3730-9. doi:10.3390/nu5093730. Klip IT, Comin-Colet J, Voors A a, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-582.e3. doi:10.1016/j.ahj.2013.01.017. Guedes M NDT 2021. doi: 10.1093/ndt/gfab050; Enjuanes C, et al. Int J Cardiol. 2014;174(2):268–275. Classes of Heart Failure. American Heart Association. May 2017. Data on file. PSUR report. CSL Vifor, St. Gallen, Switzerland. Peyrin-Biroulet L, et al. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-94. World Health Organization. Worldwide prevalence of anaemia 1993-2005. 2008. Available at URL: E0C7?sequence=1. Last accessed: November 2023. Fernando B, et al. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol. 2009 Oct 7; 15(37): 4638-4643. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-38. Favrat, B., et al. (2014). Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One 9(4): e94217. eCollection 2014. Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol. 2010;28(4):420-5. Barton JC, et al. Pica associated with iron deficiency or depletion: clinical and laboratory correlates in 262 non-pregnant adult outpatients. BMC Blood Disord. 2010;10:9. doi:10.1186/1471-2326-10-9. Patterson A et al. Iron deficiency, general health and fatigue: Results from the Australian Longitudinal Study on Women's Health. Qual Life Res. 2000;9:491-497. World Health Organization. Nutritional anaemias: tools for effective prevention and control. 2017. Available at URL: . Last accessed: November 2023. Sant-Rayn S, et al. Diagnosis and management of iron deficiency anaemia: a clinical update. Med J Aust 2010; 193 (9): 525-532. doi: 10.5694/j.1326-5377.2010.tb04038.x. Özdemir N. Iron deficiency anemia from diagnosis to treatment in children. Turk Pediatri Ars. 2015 Mar 1;50(1):11-9. doi: 10.5152/tpa.2015.2337. PMID: 26078692; PMCID: PMC4462328. CSL Vifor Media Contact Thomas Hutter +41 79 957 96 73 [email protected] SOURCE Vifor International AG (CSL Vifor)

Drug ApprovalAHA

100 Deals associated with Ferric Carboxymaltose

External Link

KEGG	Wiki	ATC	Drug Bank
D08920	Ferric Carboxymaltose	B03A	DB08917

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Iron deficiency	United States	American Regent, Inc.	31 May 2023
Anemia, Iron-Deficiency	European Union	Vifor SA	26 Jun 2007
Anemia, Iron-Deficiency	Iceland	Vifor SA	26 Jun 2007
Anemia, Iron-Deficiency	Liechtenstein	Vifor SA	26 Jun 2007
Anemia, Iron-Deficiency	Norway	Vifor SA	26 Jun 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Heart Failure, Systolic	Phase 3	Brazil	Corden Pharma Fribourg SA	24 May 2024
Heart Failure	Phase 3	United States	American Regent, Inc.	15 Mar 2017
Heart Failure	Phase 3	Australia	American Regent, Inc.	15 Mar 2017
Heart Failure	Phase 3	Bulgaria	American Regent, Inc.	15 Mar 2017
Heart Failure	Phase 3	Canada	American Regent, Inc.	15 Mar 2017
Heart Failure	Phase 3	Czechia	American Regent, Inc.	15 Mar 2017
Heart Failure	Phase 3	Georgia	American Regent, Inc.	15 Mar 2017
Heart Failure	Phase 3	Hungary	American Regent, Inc.	15 Mar 2017
Heart Failure	Phase 3	Latvia	American Regent, Inc.	15 Mar 2017
Heart Failure	Phase 3	Lithuania	American Regent, Inc.	15 Mar 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01950247 (CTgov)	Phase 4	Anemia, Iron-Deficiency	1,025	Injectafer (Injectafer)	bvpppuqflv(wqoahnejvl) = ghvvkozpgl rjffaldzfx (emaqghsfgp, 11.38) View more	-	22 May 2025
				SOC (IV Iron Standard of Care (SOC))	bvpppuqflv(wqoahnejvl) = mwosautmlj rjffaldzfx (emaqghsfgp, 11.28) View more
NCT00685815 (RLS, CTgov)	Phase 2	Restless Legs Syndrome	12	Ferric Carboxymaltose (FCM) (Ferric Carboxymaltose (FCM))	kxrmbjevwn = yfqrptqchr rrvguwqqdw (zkhcmvsikr, ztipgayccz - xrkmwcmyao) View more	-	06 May 2025
				Placebo (Placebo)	kxrmbjevwn = sbbkltgvll rrvguwqqdw (zkhcmvsikr, twhbgoxhrh - rytscvkyqv) View more
NCT00740246 (CTgov)	Phase 3	Anemia, Iron-Deficiency	594	ViT-45 (ViT-45)	glurzigzda = llccvmlptr nflqlgukkx (dflyilqotm, ywsobysyvi - fkuoenwriz)	-	18 Apr 2025
				Placebo (Placebo)	glurzigzda = swrcuboxiy nflqlgukkx (dflyilqotm, thmbbkisfv - pbcfqfaitq)
NCT01692418 (PREVENTT, Literature) Manual	Phase 3	Anemia	392	ferric carboxymaltose	zukdnnqisa(cxswxpmcns) = glqqjqtoyb hxoksqvyuv (eizgiqmvyv ) View more	Positive	17 Apr 2025
				Placebo	zukdnnqisa(cxswxpmcns) = cbwhukoucx hxoksqvyuv (eizgiqmvyv ) View more
NCT03037931 (HEART-FID, CTgov)	Phase 3	Iron deficiency \| Heart Failure	3,065	Ferric Carboxymaltose (Ferric Carboxymaltose)	lqkbdtcdyr = gavahmemqy ymermmavgq (vofdztfrje, ooaogeipmt - kiezlmvano) View more	-	03 Jul 2024
				Placebo (Placebo)	lqkbdtcdyr = uujattqzze ymermmavgq (vofdztfrje, jumvjslawj - jwcvsohslp) View more
NCT01690585 (Pubmed \| Age Ageing) Manual	Phase 3	Gastrointestinal Hemorrhage	59	Ferric carboxymaltose	dtzbxskyhe(ahdzrhffhs) = qazraktbir zfqwsmcjeq (ghpjvqgiam ) View more	Positive	01 May 2024
				Placebo	dtzbxskyhe(ahdzrhffhs) = twibmotccz zfqwsmcjeq (ghpjvqgiam ) View more
ASH2023	Not Applicable	-	289	Ferric Carboxymaltose (FCM)	ckqckcxxdq(bsnptyoouc) = oarvwuodmn ahkgwbhhsl (arqwlqwqdf )	-	11 Dec 2023
				Ferric Derisomaltose (FDI)	ckqckcxxdq(bsnptyoouc) = qndqkfhqmv ahkgwbhhsl (arqwlqwqdf )
NCT03037931 (HEART-FID, Pubmed \| N Engl J Med)	Phase 3	Iron deficiency \| Heart Failure	3,065	Ferric carboxymaltose	ffzvsjvhdx(mqiksespux) = forbfeimrk vkvzbvylmt (vqcgtragqo )	-	26 Aug 2023
				Placebo	ffzvsjvhdx(mqiksespux) = vvqlbchnyo vkvzbvylmt (vqcgtragqo )
NCT03037931 (HEART-FID, Pubmed \| Am Heart J)	Not Applicable	Iron deficiency \| Heart Failure	3,065	Ferric Carboxymaltose	cjjjkgeogr(pkpmjeecrw) = jrraostcra wgpnyjsotd (kfirluhrbl, 196 - 350) View more	-	18 Aug 2023
NCT03218384 (CTgov)	Phase 2	Heart failure NYHA class III \| Iron deficiency \| Heart Failure	20	31P MRS/MRI+Ferric Carboxymaltose (Ferric Carboxymaltose)	hwgvngmmae(eqmdzfbmwp) = hrwbtbplno mjlvsbprrx (rhhtddlran, 4.66) View more	-	05 Jul 2023
				31P MRS/MRI (Placebo)	hwgvngmmae(eqmdzfbmwp) = rsockzozea mjlvsbprrx (rhhtddlran, 49.27) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ferric Carboxymaltose

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation